Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Excessive iron absorption is one of the main features of β-thalassemia and can lead to severe morbidity and mortality. Serial analyses of β-thalassemic mice indicate that while hemoglobin levels decrease over time, the concentration of iron in the liver, spleen, and kidneys markedly increases. Iron overload is associated with low levels of hepcidin, a peptide that regulates iron metabolism by triggering degradation of ferroportin, an iron-transport protein localized on absorptive enterocytes as well as hepatocytes and macrophages. Patients with β-thalassemia also have low hepcidin levels. These observations led us to hypothesize that more iron is absorbed in β-thalassemia than is required for erythropoiesis and that increasing the concentration of hepcidin in the body of such patients might be therapeutic, limiting iron overload. Here we demonstrate that a moderate increase in expression of hepcidin in β-thalassemic mice limits iron overload, decreases formation of insoluble membrane-bound globins and reactive oxygen species, and improves anemia. Mice with increased hepcidin expression also demonstrated an increase in the lifespan of their red cells, reversal of ineffective erythropoiesis and splenomegaly, and an increase in total hemoglobin levels. These data led us to suggest that therapeutics that could increase hepcidin levels or act as hepcidin agonists might help treat the abnormal iron absorption in individuals with β-thalassemia and related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since hepcidin arises as a key iron-regulated gene due to its function as a sensor for systemic iron availability, several strategies are envisioned to manipulate its expression [81].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [81]
In the citing paper
“Thus, transgenic expression of hepcidin prevented iron overload in Hfe−∕− (Nicolas et al., 2003) and Hbbth3∕+ (Gardenghi et al., 2010) mice, models of HH and β-thalassemia intermedia, respectively.”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Gardenghi et al., 2010
In the citing paper
“Moreover, manipulation of hepcidin levels by these strategies also improved erythropoiesis in Hbbth3∕+ mice (Gardenghi et al., 2010; Nai et al., 2012).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Gardenghi et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationHepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 3×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“In the latter group of mice, egress of iron from macrophages was not expected to be altered since Hamp1 is extremely low under conditions of iron deficiency (17).”
BackgroundLEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 3×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundChen, K., Liu, J., Heck, S., Chasis, J. A., An, X., & Mohandas, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909296106 · Cited by 524 · cited 14×
“This assay allows the separation of erythroid cells into distinct populations corresponding to proerythroblasts (fraction I), basophilic (II), polychromatic (III), orthochromatic cells, and reticulocytes (IV), and mature rbc (V) (Supplemental Figure 6, only spleen is shown; similar results were observed in the BM) (18…”
MethodResultInfluentialSelf-citationMcEwen, E., Kedersha, N., Song, B., Scheuner, D., Gilks, N., Han, A., Chen, J.-J., Anderson, P., & Kaufman, R. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412882200 · Cited by 447 · cited 1×
“Previously presented data demonstrate that the absence of heme-regulated inhibitor (HRI) kinase, which controls Hb synthesis (25), exacerbates the β-thalassemia phenotype (26), while lack of heme exporter feline leukemia virus subgroup C cellular receptor (FLVCR), which controls heme export (27), impairs rbc formation…”
BackgroundHepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445 · cited 1×
“Similarly, low HAMP levels have been measured in the urine of patients with β-thalassemia (15), further supporting this hypothesis.”
BackgroundSelf-citationDisorders of hemoglobin genetics, pathophysiology, and clinical management
Steinberg, M. H. (2001) · Cited by 438
Identification of a Human Heme Exporter that Is Essential for Erythropoiesis
Quigley, J. G., Yang, Z., Worthington, M. T., Phillips, J. D., Sabo, K. M., Sabath, D. E., Berg, C. L., Sassa, S., Wood, B. L., & Abkowitz, J. L. (2004) · Cell · doi:10.1016/j.cell.2004.08.014 · Cited by 430 · cited 1×
“Previously presented data demonstrate that the absence of heme-regulated inhibitor (HRI) kinase, which controls Hb synthesis (25), exacerbates the β-thalassemia phenotype (26), while lack of heme exporter feline leukemia virus subgroup C cellular receptor (FLVCR), which controls heme export (27), impairs rbc formation…”
BackgroundSurvival and Complications in Thalassemia
BORGNA‐PIGNATTI, C., CAPPELLINI, M. D., DE STEFANO, P., DEL VECCHIO, G. C., FORNI, G. L., GAMBERINI, M. R., GHILARDI, R., ORIGA, R., PIGA, A., ROMEO, M. A., et al. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.006 · Cited by 426 · cited 1×
“NTBI serves as a catalyst for the formation of ROS, which can cause myocyte damage, arrhythmias, and congestive heart failure, the main causes of death in patients with β-thalassemia (22).”
Background
Cited by
Items 101–200 of 219
Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
Bou‐Fakhredin, R., Bazarbachi, A. H., Chaya, B. F., Sleiman, J., Cappellini, M. D., & Taher, A. T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122778 · Cited by 44
“They are known to increase the levels of endogenous hepcidin, thereby decreasing iron absorption from the GI tract, increasing the redistribution of iron to macrophages, and limiting endorgan toxicity [46].”
BackgroundInfluentialIron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory
Donker, A. E., Schaap, C., Novotny, V. M. J., Smeets, R., Peters, T. M. A., van den Heuvel, L. P., Raphaël, M. F., Rijneveld, A. W., Appel, I. M., Vlot, A. J., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24561 · Cited by 43
“In b - thalassemia mice, TMRPSS6 defects counteract the low serum hepcidin levels, thereby attenuating iron overload and anemia [37,49,50].”
Silencing airway epithelial cell-derived hepcidin exacerbates sepsis-induced acute lung injury
Chen, Q. X., Song, S. W., Chen, Q. H., Zeng, C. L., Zheng, X., Wang, J. L., & Fang, X. M. (2014) · Critical Care · doi:10.1186/s13054-014-0470-8 · Cited by 38
“Hepcidin binds to the iron export protein ferroportin and induces its internalization and degradation, which leads to decreased cellular iron export and increased intracellular iron retention [16,17].”
BackgroundAltered erythropoiesis and iron metabolism in carriers of thalassemia
Guimarães, J. D. S., Cominal, J. G., Silva‐Pinto, A. C., Olbina, G., Ginzburg, Y. Z., Nandi, V., Westerman, M. E., Rivella, S., & de Souza, A. M. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12464 · Cited by 42
Self-citationPeroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis
Mattè, A., Falco, L. D., Federti, E., Cozzi, A., Iolascon, A., Levi, S., Mohandas, N., Zamò, A., Bruno, M., Lebœuf, C., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7051 · Cited by 38
Self-citationArtuso, I., Lidonnici, M. R., Altamura, S., Mandelli, G., Pettinato, M., Muckenthaler, M. U., Silvestri, L., Ferrari, G., Camaschella, C., & Nai, A. (2018) · Blood · doi:10.1182/blood-2018-05-852277 · Cited by 38
Fisher, A. L., & Babitt, J. L. (2021) · Developmental Dynamics · doi:10.1002/dvdy.372 · Cited by 43
Hepatic Hepcidin Protects against Polymicrobial Sepsis in Mice by Regulating Host Iron Status
Zeng, C., Chen, Q., Zhang, K., Chen, Q., Song, S., & Fang, X. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000466 · Cited by 37
Siwaponanan, P., Siegers, J. Y., Ghazali, R., Ng, T., McColl, B., Ng, G. Z., SUTTON, P. R. N., Wang, N., Ooi, I., Thiengtavor, C., et al. (2017) · Blood · doi:10.1182/blood-2016-07-730135 · Cited by 40
Lertsuwan, K., Wongdee, K., Teerapornpuntakit, J., & Charoenphandhu, N. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0600-1 · Cited by 45
Coffey, R., Jung, G., Olivera, J. D., Karin, G., Pereira, R. C., Nemeth, E., & Ganz, T. (2021) · Blood · doi:10.1182/blood.2021014054 · Cited by 38
Self-citationRole of Iron in Aging Related Diseases
Chen, W. J., Kung, G. P., & Gnana‐Prakasam, J. P. (2022) · Antioxidants · doi:10.3390/antiox11050865 · Cited by 48
“Preclinical studies in mouse models of iron overload have shown that long acting hepcidin analogs, also referred to as minihepcidins [135,136], and antisense oligonucleotides targeting TMPRSS6, a metalloprotease that inhibits endogenous hepcidin production [137], effectively decrease iron load, improve erythropoiesis,…”
BackgroundAndrews, N. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmcibr1112780 · Cited by 43
Self-citationCirculating iron levels influence the regulation of hepcidin following stimulated erythropoiesis
Mirciov, C. S. G., Wilkins, S. J., Hung, G. C. C., Helman, S. L., Anderson, G. J., & Frazer, D. M. (2018) · Haematologica · doi:10.3324/haematol.2017.187245 · Cited by 35
“Certain mouse models of b-thalassemia exhibit high transferrin saturation yet continue to load with iron due to low hepcidin levels.(37) It is likely that, in these instances, the expansion of the erythroid marrow due to chronic C.”
BackgroundAnimal Models of Normal and Disturbed Iron and Copper Metabolism
Wang, X., Garrick, M. D., & Collins, J. F. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz172 · Cited by 37
Ren, F., Qian, X.-H., & Qian, X. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.02.088 · Cited by 35
Recent trends in treatment of thalassemia
El-Beshlawy, A. M., & El-Ghamrawy, M. (2019) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2019.01.006 · Cited by 36
Saliba, A. N., Rassi, F. A. E., & Taher, A. T. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1126176 · Cited by 31
Morbidities in non‐transfusion‐dependent thalassemia
Saliba, A. N., & Taher, A. T. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13083 · Cited by 35
Liu, J., Liu, W., Liu, Y., Miao, Y., Guo, Y., Song, H., Wang, F., Zhou, H., Ganz, T., Yan, B., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209874 · Cited by 30
“suitable agonists represents a promising strategy to prevent iron accumulation in HH, β-thalassemia and other iron-loading conditions.(5,6)”
BackgroundStudy of Serum Hepcidin in Hereditary Hemolytic Anemias
El-Beshlawy, A. M., Alaraby, I., Kader, M. S. E. M. A., Ahmed, D. H., & Abdelrahman, H. E. M. (2012) · Hemoglobin · doi:10.3109/03630269.2012.721151 · Cited by 33
“The defect in β-globin synthesis generates chronic anemia, which exacerbates IE and promotes extramedullary hematopoiesis, splenomegaly and iron overload (27).”
BackgroundAngelucci, E., Cianciulli, P., Finelli, C., Mecucci, C., Voso, M. T., & Tura, S. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.001 · Cited by 29
Strategies to Interfere with Tumor Metabolism through the Interplay of Innate and Adaptive Immunity
Mora, J., Mertens, C., Meier, J. K., Fuhrmann, D. C., Brüne, B., & Jung, M. (2019) · Cells · doi:10.3390/cells8050445 · Cited by 27
“Increased hepcidin levels cause anemia, while decreased expression is a causative feature in most primary iron overload diseases [72,73].”
BackgroundThe Role of Iron in Benign and Malignant Hematopoiesis
Sinha, S., Pereira-Reis, J., Guerra, A., Rivella, S., & Duarte, D. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8155 · Cited by 30
“Using antisense nucleotides and lipid nanoparticle siRNAs targeting TMPRSS6, researchers were able to mitigate iron overload and improve ineffective erythropoiesis in b -thalassemic mouse models (30, 56, 67, 150).”
Self-citationPorter, J. B., Taher, A. T., Viprakasit, V., Kattamis, A., Coates, T. D., Garbowski, M., Dürrenberger, F., Manolova, V., Richard, F., & Cappellini, M. D. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1935854 · Cited by 30
“tion, iron overload from hepcidin insufficiency appears to exacerbate ineffective erythropoiesis [37], and it has been proposed that modulation of iron homeostasis could improve ineffective erythropoiesis, thereby ameliorating anemia [7].”
BackgroundRecent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation
Man, Y., Lu, Z., Yao, X., Gong, Y., Yang, T., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911174 · Cited by 32
“Additionally, upregulation of ferritin (129) and transferrin infusion (130) improve BM hematopoietic function induced by IO in mice; further studies are required to confirm its clinical feasibility.”
BackgroundDeferasirox improves hematopoiesis after allogeneic hematopoietic SCT
Visani, G., Guiducci, B., Giardini, C., Loscocco, F., Ricciardi, T., & Isidori, A. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.213 · Cited by 27
New strategies to target iron metabolism for the treatment of beta thalassemia
Oikonomidou, P. R., Casu, C., & Rivella, S. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13018 · Cited by 28
Self-citationŞıvgın, S., & Eser, B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1682-8 · Cited by 27
Targeting a new regulator of erythropoiesis to alleviate anemia
Paulson, R. F. (2014) · Nature Medicine · doi:10.1038/nm.3524 · Cited by 26
Exploring the erythroblastic island
Socolovsky, M. (2013) · Nature Medicine · doi:10.1038/nm.3156 · Cited by 28
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation
Chauhan, W., Shoaib, S., Fatma, R., Zaka‐ur‐Rab, Z., & Afzal, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15343 · Cited by 32
“Indeed, Hbb thalassaemic animals modestly overexpressing hepcidin have been shown to have lower iron levels in the blood, liver, spleen and kidney, and improved IE, RBC survival and morphology.(48,134) Similarly, the absence of Tmprss6 (Tmprss6 Hbb), 1 of the primary suppressors of hepcidin expression, leads to reduce…”
BackgroundWang, C., Fang, Z., Zhu, Z., Liu, J., & Chen, H. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.05.002 · Cited by 30
Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice
Casu, C., Liu, A., Rosa, G. D., Low, A., Suzuki, A., Sinha, S., Ginzburg, Y. Z., Abrams, C. S., Aghajan, M., Guo, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251995 · Cited by 29
Self-citationHepcidin and Erythropoietin Level in Sickle Cell Disease
Johnkennedy, N., Uche, U. B., Udujih, H. I., Chidozie, N. J., Obeagu, E. I., & Oluchi, A.-A. (2015) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2015/17480 · Cited by 24
“This conversion could be controlled by alphaantitrypsin [6].”
BackgroundOlivera, J. D., Zhang, V., Nemeth, E., & Ganz, T. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009307 · Cited by 29
“The Hbb mouse (abbreviated here as Th3/+ or in figures as Th3), a model of thalassemia intermedia, recapitulates the following aspects of the phenotype observed in humans: low Hb, altered erythrocyte morphology, decreased erythrocyte survival with increased reticulocyte count, extramedullary erythropoiesis, splenomega…”
BackgroundSelf-citationA chemical screen identifies small molecules that regulate hepcidin expression
Gaun, V., Patchen, B., Volovetz, J., Zhen, A. W., Andreev, A., Pollastri, M. P., & Fraenkel, P. G. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.06.002 · Cited by 22
Hepcidin as a therapeutic target in iron overload
Sandnes, M., & Reikvam, H. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2443081 · Cited by 27
“Limited iron overload upon increased hepcidin expression is also seen in murine models of untransfused β-thalassemia with an overall reduction in formation of ROS and improved anemia by reversing ineffective erythropoiesis [28].”
Fang, Z., Zhu, Z., Zhang, H., Peng, Y., Liu, J., Lu, H., Jiang, L., Liang, L., Xia, S., Wang, Q., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16156 · Cited by 25
“Given that therapeutic strategies using HAMP activation have been shown to improve ineffective erythropoiesis and reverse anaemia in b-thalassaemia (Gardenghi et al, 2010; Li et al, 2010; Guo et al, 2013; Suragani et al, 2014b; Schmidt et al, 2015; Casu et al, 2016; Chen et al, 2016), SMURF1…”
BackgroundSelf-citationYuki, K. E., Eva, M. M., Richer, E., Chung, D., Paquet, M., Cellier, M., Canonne-Hergaux, F., Vaulont, S., Vidal, S. M., & Malo, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055331 · Cited by 20
Anderson, D. S., Kirchner, M., Kellogg, M. D., Kalish, L. A., Jeong, J., Vanasse, G. J., Berliner, N., Fleming, M. D., & Steen, H. (2011) · Analytical Chemistry · doi:10.1021/ac2020905 · Cited by 20
Saad, H. K. M., Rahman, A. A. A., Ghani, A. S. A., Taib, W. R. W., Ismail, I., Johan, M. F., Al-wajeeh, A. S., & Al‐Jamal, H. A. N. (2022) · Biomedicines · doi:10.3390/biomedicines10010189 · Cited by 29
Iron age: novel targets for iron overload
Casu, C., & Rivella, S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.216 · Cited by 20
Self-citationA computational model to understand mouse iron physiology and disease
Parmar, J. H., & Mendes, P. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006680 · Cited by 22
Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide
Taher, A. T., & Cappellini, M. D. (2014) · Drugs · doi:10.1007/s40265-014-0299-0 · Cited by 20
Tantiworawit, A., Khemakapasiddhi, S., Rattanathammethee, T., Hantrakool, S., Chai‐Adisaksopha, C., Rattarittamrong, E., Norasetthada, L., Charoenkwan, P., Srichairatanakool, S., & Fanhchaksai, K. (2021) · Bioscience Reports · doi:10.1042/bsr20203352 · Cited by 25
A tincture of hepcidin cures all: the potential for hepcidin therapeutics
Bartnikas, T. B., & Fleming, M. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci45043 · Cited by 16
Role of Hepcidin in Iron Metabolism and Potential Clinical Applications
Grimes, C. N., Giori, L., & Fry, M. M. (2012) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2011.10.002 · Cited by 21
Forni, G. L., Podestà, M., Musso, M., Piaggio, G., Musallam, K. M., Balocco, M., Pozzi, S., Rosa, A., & Frassoni, F. (2012) · Haematologica · doi:10.3324/haematol.2012.076240 · Cited by 16
“Moreover, there is mounting evidence from animal studies that treatment of iron overload affects erythropoietic capacity and leads to improvements in hemoglobin level and red cell survival.(7-9) Similar evidence from clinical studies is limited and has been primarily reported for patients with myelodysplastic syndrome…”
BackgroundInhibiting the hepcidin inhibitor for treatment of iron overload
Silvestri, L. (2013) · Blood · doi:10.1182/blood-2012-12-472597 · Cited by 14
Iron and erythropoiesis: A mutual alliance
Silvestri, L., & Nai, A. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.05.002 · Cited by 19
Peripheral expression of hepcidin gene in Egyptian β-thalassemia major
Enein, A. A., El-Beshlawy, A. M., Hamdy, M. M., Shaheen, I. A. E.-M., El-Saadany, Z. A., Samir, A., & El-Samie, H. A. (2015) · Gene · doi:10.1016/j.gene.2015.03.048 · Cited by 14
“It is now a well-validated target therapy, by modulating its expression and/or activity, which not only treates the secondary iron overload associated with β-thalassemia, but also ameliorates the anemia itself in animal models of the disease (Gardenghi et al., 2010; Ramos et al., 2012).”
BackgroundHepcidin and its multiple partners: Complex regulation of iron metabolism in health and disease
Ginzburg, Y. Z. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2023.03.001 · Cited by 20
Self-citationThree signalling pathways for iron overload in osteoporosis: a narrative review
Zou, L., Chen, G., Rong, Y., Tang, C., Lv, X., & Fan, Y. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05588-4 · Cited by 15
“In line with this, overexpression of the HAMP1 gene to a certain extent, reduced the iron content in the tissues of beta-thalassemia model mice to normal levels [28].”
Striking the target in iron overload disorders
Finberg, K. E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68889 · Cited by 18
Prospects for a hepcidin mimic to treat β-thalassemia and hemochromatosis
Parrow, N. L., Gardenghi, S., & Rivella, S. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.22 · Cited by 17
Self-citationChappell, M., Breda, L., Tricoli, L., Guerra, A., Jarocha, D. J., Castracani, C. C., Papp, T. E., Tanaka, N., Hamilton, N., Triebwasser, M. P., et al. (2024) · Blood · doi:10.1182/blood.2023023349 · Cited by 13
Self-citationRole of HAMP Genetic Variants on Pathophysiology of Iron Deficiency Anemia
Pandey, S., Pandey, S. K., & Shah, V. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0707-9 · Cited by 13
Oxidative Stress and Iron Overload in β-Thalassemia: An Overview
Sposi, N. M. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90492 · Cited by 18
El-Maleky, N. F., & Ebrahim, R. H. (2018) · Electromagnetic Biology and Medicine · doi:10.1080/15368378.2018.1531423 · Cited by 14
“Thus, measuring hepcidin would be of benefit to establish optimal treatment (Bregman et al., 2013; Gardenghi et al., 2010).”
BackgroundIncreasing serum transferrin to reduce tissue iron overload due to ineffective erythropoiesis
Tolosano, E. (2015) · Haematologica · doi:10.3324/haematol.2015.124966 · Cited by 14
“lassemic mice placed on a low-iron diet or engineered to overexpress hepcidin to limit iron availability.(9) Furthermore, administration of apoTf to hypotransferrinemic mice, which suffered from an iron-restricted anemia associated with tissue iron over-”
BackgroundCurrent Landscape of Hepcidin Therapeutics
Nai, A., Silvestri, L., Asperti, M., & Vinchi, F. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_26 · Cited by 15
Strategies for managing transfusional iron overload: conventional treatments and novel strategies
Sheth, S. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000499 · Cited by 11
Manalo, D. J., Baek, J. H., Buehler, P. W., Struble, E. B., Abraham, B., & Alayash, A. I. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.085 · Cited by 10
Al‐Hakeim, H. K., Al-Khakani, M. F., & Al-Kindi, M. A. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/38158 · Cited by 9
“Currently, thalassemias are managed with chelation therapy, but exogenous transferrin [2], exogenous hepcidin, [3], or hepcidin signaling agonists [4] may be effective options in the future.”
BackgroundProtein-based therapeutic for anemia caused by dyserythropoiesis
Arlet, J., Guillem, F., Lamarque, M., Dussiot, M., Maciel, T. T., Moura, I. C., Hermine, O., & Courtois, G. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1240622 · Cited by 10
Liu, J., Zhao, J., He, J., Li, Y., Xu, J., Xiao, C., Zhang, Y., Chen, H., Hu, Y., Fan, C., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02079-z · Cited by 11
“For example, in mouse model β-thalassemia intermedia proved that transgenic overexpression of hepcidin could prevent iron metabolism disorders and regulate eryropoiesis [50].”
Wake, M., Palin, A., Belot, A., Berger, M., Lorgouilloux, M., Bichon, M., Papworth, J., Bayliss, L., Grimshaw, B., Rynkiewicz, N. K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012010 · Cited by 12
An Update on Iron Homeostasis: Make New Friends, but Keep the Old
Roy, C. N. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000190 · Cited by 11
Self-citationTHALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA
Yang, K., & Xiao, J. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.001 · Cited by 12
“15 The extramedullary hematopoiesis rate increases in patients with β -thalassemia to compensate for anemia, resulting in increased production and clearance of abnormal RBCs, with hypersplenism and increased spleen size.”
Hepcidin mediated iron homoeostasis as immune regulator in visceral leishmaniasis patients
Singh, B., Singh, S. S., & Sundar, S. (2018) · Parasite Immunology · doi:10.1111/pim.12601 · Cited by 8
Lefèbvre, T., Millot, S., Richard, E., Blouin, J., Lalanne, M., Lamrissi‐Garcia, I., Costet, P., Lyoumi, S., Gouya, L., Puy, H., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.09.141 · Cited by 9
Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?
Longo, F., & Piga, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175119 · Cited by 8
“Proof-of-principle studies indicate that a moderate increase in hepcidin expression reduces tissue iron levels, with a beneficial effect on erythropoiesis, in an NTDT mouse model [46].”
BackgroundPrise en charge actuelle des thalassémies intermédiaires
Thuret, I. (2014) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2014.07.005 · Cited by 6
Stagg, D. B., Whittlesey, R. L., Li, X., Lozovatsky, L., Gardenghi, S., Rivella, S., & Finberg, K. E. (2019) · Haematologica · doi:10.3324/haematol.2018.213371 · Cited by 6
“Transgenic hepcidin overexpression,7 low-iron diet,7 haematologica 2019; 104:e442 and transferrin injection9 improve erythropoiesis in TI mouse models; the underlying mechanism(s), while still uncertain, appear to be related to altered iron availability to EP.”
ResultInfluentialSelf-citationImpaired bone marrow microenvironment and stem cells in transfusion-dependent beta-thalassemia
Zhou, X., Huang, L., Wu, J., Qu, Y., Jiang, H., Zhang, J., Qiu, S., Liao, C., Xu, X. M., Xia, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112548 · Cited by 9
Rivella, S. (2012) · Blood · doi:10.1182/blood-2012-04-418590 · Cited by 5
Self-citationBharti, B., & Mishra, R. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2325-7 · Cited by 5
Sposi, N. M. (2015) · InTech eBooks · doi:10.5772/61716 · Cited by 9
Ayatollahi, H., Nezhad, S. F. M., Talebpour, A., Badiei, Z., & Nezami, H. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06012-2 · Cited by 7
Halawi, R., Motta, I., Taher, A. T., & Cappellini, M. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1182018 · Cited by 5
Fetal Factors Disrupt Placental and Maternal Iron Homeostasis in Murine β-Thalassemia
Yang, Y., Woloshun, R. R., Lee, J. K., Ebea, P. O., Zhu, S., Nemeth, E., Garrick, L. M., Garrick, M. D., & Collins, J. F. (2023) · Blood · doi:10.1182/blood.2022018839 · Cited by 9
Self-citationIron Deficiency, Iron Overload and Therapy
Crichton, R. R. (2016) · Wiley eBooks · doi:10.1002/9781118925645.ch11 · Cited by 4
Yu, Y., Woloshun, R. R., Lee, J. K., Ebea, P. O., Shine, J. S., Zhu, S., He, Y., & Collins, J. F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013333 · Cited by 5
“Several hepcidin-directed interventions decreased iron loading and improved the anemia in Th3/+ mice, including hepcidin agonists, 10 transgenic overexpression of hepcidin, 40 and silencing of matriptase 2, 46,47 which is a negative regulator of hepatic HAMP .”
Aydınok, Y. (2019) · ISBT Science Series · doi:10.1111/voxs.12522 · Cited by 3
Cutts, A., Chowdhury, S., Ratkay, L. G., Eyers, M., Young, C., Namdari, R., Cadieux, J. A., Chahal, N., Grimwood, M., Zhang, Z., et al. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001435 · Cited by 4
Iron Overload and Chelation Therapy in Hemoglobinopathies
Bou‐Fakhredin, R., Elias, J., & Taher, A. T. (2018) · Thalassemia Reports · doi:10.4081/thal.2018.7478 · Cited by 4
Adams, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.022 · Cited by 3
Tfr2 suppression benefits β-thalassemic erythropoiesis
Ginzburg, Y. Z., & Fleming, R. E. (2018) · Blood · doi:10.1182/blood-2018-10-876110 · Cited by 3
Self-citationSłomka, A., Koba, M., Kulwas, A., & Żekanowska, E. (2011) · Current Pharmaceutical Analysis · doi:10.2174/157341211796353309 · Cited by 3
Skerratt, S. E., Humphreys, S., Ferreira, R., Jorgensen, C. C., Warmus, J., Zhao, L., Tong, X., & Nickolls, S. A. (2016) · MedChemComm · doi:10.1039/c6md00260a · Cited by 2
Gene Therapy for Hemoglobinopathies
Dong, A., Breda, L., & Rivella, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00012-9 · Cited by 4
Self-citation(De)ironing out sickle cell disease
Das, N. K., & Shah, Y. M. (2023) · Blood · doi:10.1182/blood.2022018791 · Cited by 3
Editorial: Stress erythropoiesis
de Vasconcellos, J. F., Meier, E. R., & Parrow, N. L. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1165315 · Cited by 2
Levy, M., & Ginzburg, Y. Z. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_11 · Cited by 1
Self-citationNon-Transfusion Dependent Thalassemia: Translating Evidence to Guidelines
Harb, A., Saliba, A. N., & Taher, A. T. (2014) · Thalassemia Reports · doi:10.4081/thal.2014.4863 · Cited by 1
Pocket-sized iron regulators: one size fits all?
Subramaniam, V. N. (2016) · Blood · doi:10.1182/blood-2016-05-716043 · Cited by 1
“As proof of concept, transgenic overexpression of hepcidin prevents iron overload in an animal model of hemochromatosis,(4) and reduces iron loading and improves anemia in b-thalassemia.(5) Minihepcidins, mimetics of the hepcidin peptide with improved pharmacological properties, have been reported to have therapeutic…”
BackgroundKucine, N., & Giardina, P. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00005-2 · Cited by 1
Self-citation[Hepcidin for iron homeostasis and target therapy in ironrelated disorders].
Fan, S., Zheng, Y., & Shi, J. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.11.020 · Cited by 1
“[37] Gardenghi S, Ramos P, Marongiu MF, et al.”
BackgroundHuang, L., & Fu, R. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.08.021 · Cited by 2
“[36] Gardenghi S, Ramos P, Marongiu MF, et al.”
Background
Metadata
- Authors
- Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., Nemeth, E., Follenzi, A., An, X., Mohandas, N., Ginzburg, Y., Rachmilewitz, E. A., Giardina, P. J., Grady, R. W., & Rivella, S.
- Affiliations
- Weill Cornell Medicine (US)
- Johns Hopkins University (US)
- Duke University (US)
- University of California, Los Angeles (US)
- Albert Einstein College of Medicine (US)
- New York Blood Center (US)
- Wolfson Medical Center (IL)
- Corresponding author
- Rivella, Stefano
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-12-01
- Volume
- 120
- Issue
- 12
- Pages
- 4466-4477
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2993583
- OpenAlex
- W2163438420
- Cited by
- 220
- References
- 31
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 6 · 2021: 12 · 2020: 9 · 2019: 19 · 2018: 14 · 2017: 17 · 2016: 13 · 2015: 19 · 2014: 26 · 2013: 21 · 2012: 21
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- Cooley's Anemia Foundation
- American Portuguese Biomedical Research Fund
- National Institutes of Health (10021)
- College of Veterinary Medicine, Cornell University
- Weill Cornell Medical College
- Fundação para a Ciência e a Tecnologia (SFRH/BD/24813/2005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK055463, KO1DK065635, R01DK090554, R01DK082717, R01DK55463, K01DK065635)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- hepcidin, beta-thalassemia, iron overload, iron absorption, ferroportin, anemia, ineffective erythropoiesis, splenomegaly, reactive oxygen species, red blood cell lifespan, iron metabolism
- MeSH terms
- Animals, Base Sequence, Disease Models, Animal, Erythropoiesis, Humans, Iron, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Recombinant Proteins, Gene Expression, beta-Thalassemia, DNA Primers, Iron Overload, Iron, Dietary, Antimicrobial Cationic Peptides, Mice, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.